Treatment for hepatitis C has vastly improved with the new and highly effective Direct Acting Antivirals (DAAs). They are much less toxic which means that patients co-infected with tuberculosis and hepatitis C do not have to interrupt their vital tuberculosis treatment. Hakobyn is the first MSF patient in Armenia to have benefited from these new drugs.